Learn more about our parent company “Yuhan Corporation by watching this video.
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients (biospectator.com)
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients YH35324 is an Fc fusion protein
Yuhan
February 21, 2024